IP Library Granted Patent US 11,865,286
Granted Patent B2
US 11,865,286 · App. 16/909,695 · Granted Jan 9, 2024

Active agent delivery devices and methods of using the same

Inventors: Kiana Aran (Berkeley, CA); Jacobo Paredes (Berkeley, CA); Niren Murthy (Berkeley, CA); Dorian Liepmann (Lafayette, CA); Kunwoo Lee (Albany, CA)
Assignee: The Regents of the University of California
A61M31/002A61K9/006A61K39/0005A61M31/00A61K2039/542A61M2202/064A61M2205/3324A61M2205/3334A61M2205/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,865,286
App. No.
16/909,695
Granted
Jan 9, 2024
Kind
B2
Abstract

Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.

Claims (31)

1. A device for delivery of an active agent in the gastrointestinal tract of a subject, comprising:

a housing having a cylindrical wall, the housing adapted to be swallowed by a user;

a first reservoir in the housing containing an active agent formulation;

a second reservoir in the housing, the second reservoir configured to generate a gas from a gas generating material via a chemical reaction; and

a membrane separating the active agent formulation in the first reservoir from the gas generated by the second reservoir, the gas exerting pressure on the membrane to propel the active agent formulation out of the housing to facilitate penetration of the active agent into a layer of the gastrointestinal tract.

2. The device of claim 1 , wherein the second reservoir comprises at least one valve.

3. The device of claim 1 , wherein the device is configured to eject the active agent formulation in 10 msec or less.

4. The device of claim 1 , wherein an opening extends through the cylindrical wall extending from the first reservoir to the exterior of the device.

5. The device of claim 1 , wherein the second reservoir contains a gas generating material which produces a gas upon contact with an aqueous medium.

6. The device of claim 1 , wherein the second reservoir further includes a valve actuated by change in pH.

7. The device of claim 1 , wherein the gas generating material comprises a volatile liquid.

8. The device of claim 1 , wherein the active agent comprises a macromolecule.

9. The device of claim 8 , wherein the macromolecule comprises a protein.

10. The device of claim 1 , wherein the active agent formulation comprises a liquid.

11. The device of claim 1 , further comprising a tubular member having a planar surface.

12. The device of claim 11 , wherein the device is configured to promote contact of the tubular member with a mucosal surface in a subject.

13. The device of claim 2 , wherein the valve comprises an opening and a pH responsive material disposed in the opening.

14. The device of claim 13 , wherein the pH responsive material comprises a polymer.

15. The device of claim 2 , wherein the valve comprises a hole in a wall of the second reservoir.

16. The device of claim 2 , wherein the valve is configured to degrade or dissolve at a pH of 4 or less.

17. The device of claim 1 , wherein the second reservoir is configured to eject the active agent formulation at a pressure of from 25 kPa to 125 kPa.

18. The device of claim 2 , wherein the valve comprises a pH responsive material configured to degrade or dissolve to provide an inlet into the second reservoir in response to a change in pH.

19. A method, comprising:

administering the device of claim 1 to a subject.

20. The method of claim 19 , further comprising using the device to treat a disease condition of the subject.

21. A kit comprising:

a device according to claim 1 ; and

a packaging containing the device.

22. The kit of claim 21 , wherein the packaging comprises at least two devices according to claim 1 .

23. The kit of claim 21 , further comprising a mucosal treatment agent.

24. The device of claim 1 , wherein penetration of the active agent into a layer of the gastrointestinal tract is into a layer of the stomach or intestines.

Assignments (3)
SECURITY INTEREST Recorded Aug 15, 2025
From: BT BIDCO, INC.
To: GLAS USA LLC
Reel/Frame 072473/0861 →
SECURITY INTEREST Recorded Dec 21, 2023
From: BIORA THERAPEUTICS, INC.
To: GLAS TRUST COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 066089/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: ARAN, KIANA; PAREDES, JACOBO; MURTHY, NIREN; LIEPMANN, DORIAN; LEE, KUNWOO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 053561/0051 →
Continuity (3)
Continuation 15513110
Provisional Application 62057887 · Sep 30, 2014
Related Publication 20200316352A1 · Oct 8, 2020